-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Author: Clover
On October 8, China Biopharmaceuticals issued a corporate announcement stating that the company's self-developed innovative drug "TCR1672" had submitted an investigational new drug (IND) application to the U.
According to the announcement, TCR1672 is a second-generation highly selective P2X3 receptor antagonist, currently mainly used in the treatment of refractory chronic cough (RCC) adult patients in the respiratory field and endometriosis in the pain field and other complex internal organs Pain patients
What is a P2X3 receptor antagonist?
What is a P2X3 receptor antagonist?It is reported that in 1996, Pelleg and Hurt proved for the first time that extracellular ATP is an effective activator of sensory nerve fibers of the canine lung vagus nerve.
Image source: Bellus Health
Some structural/anatomical evidence suggests that cough reflex hypersensitivity may be specifically mediated through P2X3 receptors, which are ligand-gated ion channels in the purinergic receptor family
Therefore, antagonists that target P2X3 homotrimers have a therapeutic effect by blocking the influx of calcium ions produced by the P2X3 receptor initiated by adenosine triphosphate (ATP), thereby exerting a specific inhibitory effect on it
What is the market prospect and commercial value?
What is the market prospect and commercial value?According to public data, about 5%-10% of adults worldwide suffer from chronic cough
According to a Bellus Health corporate report, there are approximately 2.
It is worth mentioning that according to Yaozhi data query, as of now, there is no clinically approved standard drug for the treatment of chronic cough, and there are huge unmet clinical needs
Therefore, P2X3 receptor blockers are expected to become the first type of targeted therapy drugs for the treatment of refractory chronic cough (RCC) or unexplained chronic cough (UCC); it will become the most potential refractory cough in recent decades Therapeutic drugs for asthma
Who will eat the "crab" first?
Who will eat the "crab" first?Although there is no P2X3 inhibitor approved globally, the P2X3 target has become a popular research target in recent years, and domestic and foreign companies have deployed them
Research progress of some P2X3 inhibitors at home and abroad
Among them, Merck’s gefapixant (MK-7264) has made the fastest research progress.
Data deadline: February 2020
Image source: Bellus Health
Gefapixant (MK-7264) was acquired by Merck in 2016 with a USD 1.
Speaking of this, I have to mention the P2X3 receptor selective antagonist QR052107B independently developed by China's Wuhan Langlai Technology, which is also a highly selective P2X3 receptor antagonist, which is on the premise of retaining good antitussive efficacy.
In addition, Bayer also announced in September that its IIb clinical study of eliapixant (BAY1817080) for the treatment of patients with refractory chronic cough (RCC) reached the primary endpoint
Note: The original text has been deleted
references:
1.
2.
3.
https://ir.
bellushealth.
com/static-files/e26b65d5-50fb-483c-91d0-8a5c3b138cbb
